TILTomorrow today: dynamic factors predicting changes in intracranial pressure treatment intensity after traumatic brain injury

5 Shubhayu Bhattacharyay^{1,2,3,*}, Florian D van Leeuwen⁴, Erta Beqiri⁵, Cecilia

Åkerlund6, Lindsay Wilson7, Ewout W Steyerberg4, David W Nelson6 , Andrew I R

Maas8,9, David K Menon1, Ari Ercole1,10 , and the CENTER-TBI investigators and

- **participants†**
-
- 1Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.
- 2Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
- 13 ³Harvard Medical School, Boston, MA, USA.
- 14 ⁴Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden,
- The Netherlands.
- 16 ⁵ Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge,
- Cambridge, United Kingdom.
- 18 ⁶Department of Physiology and Pharmacology, Section for Perioperative Medicine and
- Intensive Care, Karolinska Institutet, Stockholm, Sweden.
- 7Division of Psychology, University of Stirling, Stirling, United Kingdom.
- ⁸Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
- 22 ⁹Department of Translational Neuroscience, Faculty of Medicine and Health Science,
- University of Antwerp, Antwerp, Belgium.
- 24 ¹⁰Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.
- *Corresponding author: sb2406@cam.ac.uk (SB)
- **†** A full list of the CENTER-TBI investigators and participants are listed after the
- acknowledgements.

ABSTRACT

 Practices for controlling intracranial pressure (ICP) in traumatic brain injury (TBI) patients admitted to the intensive care unit (ICU) vary considerably between centres. To help understand the rational basis for such variance in care, this study aims to identify the patient-level predictors of changes in ICP management. We extracted all heterogeneous data (2,008 pre-ICU and ICU variables) collected from a prospective cohort (*n*=844, 51 ICUs) of ICP-monitored TBI patients in the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study. We developed the TILTomorrow modelling strategy, which leverages recurrent neural networks to map a token-embedded time series representation of all variables (including missing values) to an ordinal, 40 dynamic prediction of the following day's five-category therapy intensity level (TIL^(Basic)) score. With 20 repeats of 5-fold cross-validation, we trained TILTomorrow on different variable sets and applied the TimeSHAP (temporal extension of SHapley Additive exPlanations) algorithm to estimate variable contributions towards predictions of next-day 44 changes in TIL^(Basic). Based on Somers' D_{xy} , the full range of variables explained 68% 45 (95% CI: 65–72%) of the ordinal variation in next-day changes in TIL^(Basic) on day one and 46 up to 51% (95% CI: 45–56%) thereafter, when changes in TIL^(Basic) became less frequent. Up to 81% (95% CI: 78–85%) of this explanation could be derived from non-treatment variables (i.e., markers of pathophysiology and injury severity), but the prior trajectory of ICU management significantly improved prediction of future de-escalations in ICP- targeted treatment. Whilst there was no significant difference in the predictive discriminability (i.e., area under receiver operating characteristic curve [AUC]) between next-day escalations (0.80 [95% CI: 0.77–0.84]) and de-escalations (0.79 [95% CI: 0.76– $\,$ 0.82]) in TIL^(Basic) after day two, we found specific predictor effects to be more robust with de-escalations. The most important predictors of day-to-day changes in ICP management included preceding treatments, age, space-occupying lesions, ICP, metabolic derangements, and neurological function. Serial protein biomarkers were also important and may serve a useful role in the clinical armamentarium for assessing therapeutic 58 needs. Approximately half of the ordinal variation in day-to-day changes in TIL^(Basic) after day two remained unexplained, underscoring the significant contribution of unmeasured factors or clinicians' personal preferences in ICP treatment. At the same time, specific dynamic markers of pathophysiology associated strongly with changes in treatment intensity and, upon mechanistic investigation, may improve the timing and personalised targeting of future care.

MAIN TEXT

Introduction

 When traumatic brain injury (TBI) patients are admitted to the intensive care unit (ICU), a core focus of their care is to protect and promote potential recovery in brain tissue by either preventing or mitigating raised intracranial pressure (ICP).¹ To date, the heterogeneous pathophysiological mechanisms that elevate ICP after TBI are not 72 sufficiently characterised for patient-tailored treatment (i.e., precision medicine).^{2,3} 73 Therefore, consensus-based guidelines^{4,5} encourage a precautionary, stepwise approach⁶ to ICP management, in which therapeutic intensity – defined by the perceived risk and complexity of each treatment plan – is incrementally escalated until adequate ICP control is achieved. The overall intensity of a patient's ICP management can be measured on the latest Therapy Intensity Level (TIL) scale,⁷ which was developed by the 78 interagency TBI Common Data Elements (CDE) scheme⁸ and prospectively validated 79 thereafter.^{7,9}

 An analysis of high-TIL treatment administration across 52 ICUs participating in the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study^{10,11} revealed frequent deviation from the recommended stepwise approach, even 84 vith ICP monitoring.¹² In fact, there was substantial between-centre variation in ICP management (according to TIL) without commensurate variation in six-month functional 86 outcome on the Glasgow Outcome Scale – Extended (GOSE).^{13,14} Baseline injury severity factors, imaging results, and ICP explained only 8.9% of the pseudo-variance in 88 dichotomised high-TIL treatment use.¹² These results raised the questions about whether contemporary ICP management is performed in a systematic, rational manner in practice and whether some patients are being exposed to unnecessary risks with high-TIL therapies. Answering these questions requires consideration of a patient's full, time- varying clinical course as well as a more detailed representation of different levels of the TIL scale.

 As a first step towards answering the questions above, we aim to identify factors associated with ICP-targeted treatment decisions on an individual patient level. 97 Expanding upon our previous work, $13,15$ we propose a modelling strategy (TILTomorrow) 98 which dynamically predicts next-day TIL^(Basic) – the five-category version of TIL – from all pre-ICU and ICU data prospectively recorded for the CENTER-TBI study (Fig. 1). Our primary objective in developing TILTomorrow was to determine how well a patient's full clinical course can predict upcoming changes in ICP treatment intensity. Our second objective was to estimate the differential contribution of pathophysiological severity, the preceding trajectory of treatment, and unmeasured factors (e.g., personal treatment 104 preferences) towards explanation of next-day changes made to TIL^(Basic). Our third objective was to mine the full dataset for dynamic predictors of day-to-day changes in $TIL^(Basic)$.

 are 95% confidence intervals derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across the patient population and across the 20 repeated five-fold cross-validation partitions. (**a**) Illustration of the TILTomorrow dynamic prediction task on a sample patient's timeline of ICU stay. The objective of the task is to predict the next-day TIL^(Basic) score at each calendar day of a patient's ICU stay. The prediction is dynamic, updated for each calendar day, and must account for temporal variation of variables across all preceding days using a time-series model (*ft*). (**b**) Illustration of the TILTomorrow modelling strategy on a sample patient's timeline of ICU stay. Each patient's ICU stay is first discretised

 into non-overlapping time windows, one for each calendar day. From each time window, values for up to 979 dynamic variables were combined with values for up to 1,029 static variables to form the variable set. The variable values were converted to tokens by discretising numerical values into 20-quantile bins from the training set and removing special formatting from text-based entries. Through an embedding layer, a vector was learned for each token encountered in the training set, and tokens were replaced with these vectors. A positive relevance weight, also learned for each token, was used to weight-average the vectors of each calendar day into a single, low-dimensional vector. The sequence of low-dimensional vectors representing a patient's ICU stay were fed into a gated recurrent neural network (RNN). The RNN outputs 125 were then decoded at each time window into an ordinal prognosis of next-day TIL^(Basic) score. The highest-126 intensity treatments associated with each threshold of TIL^(Basic) are decoded in Table 1. (c) Probability 127 calibration slope, at each threshold of next-day TIL^(Basic), for models trained on the full variable set. The ideal calibration slope of one is marked with a horizontal orange line. (**d**) Ordinal probability calibration curves at four different days after ICU admission. The diagonal dashed line represents the line of perfect calibration. The values in each panel correspond to the maximum absolute error (95% confidence interval) between the curve and the perfect calibration line. Abbreviations: CT=computerised tomography, ER=emergency room, *ft*=time-series model, GRU=gated recurrent unit, Hx=history, ICP=intracranial pressure, ICU=intensive care unit, LSTM=long short-term memory, N/A=not available, NF-L=neurofilament 134 light chain, SES=socioeconomic status, TIL=Therapy Intensity Level, TIL^(Basic) =condensed, five-category TIL scale as defined in Table 1, VE=vascular endothelial.

Methods

Study design and participants

 CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65 142 medical centres across 18 European countries and Israel.^{10,11} Patients were recruited between 19 December 2014 and 17 December 2017 if they met the following criteria: (1) presentation within 24 hours of a TBI, (2) clinical indication for a computerised tomography (CT) scan, and (3) no severe pre-existing neurological disorder. In accordance with relevant laws of the European Union and the local country, ethical approval was obtained for each site, and written informed consent by the patient or legal representative was documented electronically. The list of sites, ethical committees, approval numbers, and approval dates can be found online: [https://www.center-](https://www.center-tbi.eu/project/ethical-approval) [tbi.eu/project/ethical-approval.](https://www.center-tbi.eu/project/ethical-approval) The project objectives and design of CENTER-TBI have 151 been described in detail previously.^{10,11}

 In this work, we apply the following additional inclusion criteria: (1) primary admission to the ICU, (2) at least 16 years old at ICU admission, (3) at least 24 hours of ICU stay, (4) invasive ICP monitoring, (5) no decision to withdraw life-sustaining therapies (WLST) on the first day of ICU stay, and (6) availability of daily TIL assessments from at least two consecutive days.

Therapy intensity level (TIL)

 The endpoint for the TILTomorrow dynamic prediction task (Fig. 1a) is the next-day $TIL^{(Basic)}$ score. The TIL^(Basic) scale was developed through an international expert panel 163 to serve as a five-category summary of the full, -point TIL score.⁸ TIL^(Basic) categorises overall ICP treatment intensity over a given period of time by selecting the highest 165 classification of ICP control amongst all treatments administered in that period of time, as 166 defined in Table 1. By convention, a decompressive craniectomy for refractory intracranial 167 hypertension is scored with $TIL^{(Basic)}=4$ (i.e., extreme ICP control) for every subsequent 168 timepoint. As described later, we account for this effect in our analysis by: (1) referencing 169 TILTomorrow performance against simply carrying forward the last-available TIL^(Basic) 170 score and against models trained without treatment (e.g. incidence of decompressive 171 craniectomy) or clinician-impression (e.g., reason for decompressive craniectomy) 172 variables, and (2) focusing only on variables that occur at least a day before a change in 173 TIL(Basic). Since daily use of TIL(Basic) was prospectively validated,⁷ we calculate the 174 \blacksquare TIL^(Basic) score over each available calendar day of a patient's ICU stay. For the CENTER-175 TBI study, information pertaining to the TIL^(Basic) treatments (Table 1) was recorded on 176 days 1–7, 10, 14, 21, and 28 of ICU stay. TIL^(Basic) score calculations were excluded on 177 or after the day of any WLST decision. As an overall summary metric, we also calculated 178 TIL^(Basic)_{median} – the median of the daily TIL^(Basic) scores over days 1–7 of ICU stay.

179

 We elected not to use the full TIL score as the model endpoint since it is a point-sum (rather than a truly categorical) score, and the same value changes in TIL can be the result of changing treatments across different intensities. For instance, administering head elevation, low-volume cerebrospinal fluid drainage, and low-dose mannitol is 184 numerically 'equivalent' to performing a last-resort decompressive craniectomy.⁷ On the 185 contrary, changes in $TIL^(Basic)$ correspond to transitions across specific, interpretable bands of treatment intensity (Table 1).

Table 1. TIL(Basic) 188 **scale treatments and representation in study population**

189 The TIL^(Basic) scale was developed by Maas *et al.*⁸ and prospectively validated by Bhattacharyay *et al.*⁷ The TIL^(Basic) score is determined by selecting

190 the highest classification of ICP control (first column) among all the ICP-targeting treatments (second column) administered to a patient over a

191 calendar day. The study representation of each TIL^(Basic) category and each ICP-targeting treatment is the count (and percentage) of patients who

192 received the corresponding (category of) treatment in the study population as well as the count (and percentage) of centres who administered the

193 corresponding (category of) treatment in the study population.

194 *If a decompressive craniectomy is performed as a last resort for refractory intracranial hypertension, its score is included in the day of the operation 195 and in every subsequent day of ICU stay.

196 Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, ICU=intensive care unit, PaCO2=partial 197 pressure of carbon dioxide in arterial blood, TIL=Therapy Intensity Level scale, TIL^(Basic)=condensed TIL scale.

¹⁹⁸ *Model variables*

199

 We extracted all variables collected before and during ICU stays for the CENTER-TBI 201 core study¹¹ (v3.0, ICU stratum) using Opal database software.¹⁶ These variables were sourced from medical records and online test results and include structured (i.e., numerical, binary, or categorical), unstructured (i.e., free text), and missing values. We manually excluded variables which explicitly indicate death or WLST (Supplementary Table S1), and, if a decision to WLST was made during any point of a patient's ICU stay, we only extracted model variables before the timestamp of WLST decision. We also added features extracted from automatically segmented and expert-corrected high- resolution CT and magnetic resonance (MR) images. These features correspond to the type, location, and volume of space-occupying lesions, and the process of their extraction 210 has been described in detail previously.^{17,18} In total, we included 2,008 variables: 1,029 static (i.e., fixed at ICU admission) variables and 979 dynamic variables (i.e., collected during ICU stay) with varying sampling frequencies. We qualitatively organised the variables into the nine categories listed in Table 2 and further indicated whether variables represented an intervention during ICU admission (e.g., administration and type of glucose management) or a physician-based impression (e.g., reason for not pursuing intracranial surgery following CT scan, Supplementary Table S2). Descriptions for each of the variables can be viewed online at the CENTER-TBI data dictionary: [https://www.center-tbi.eu/data/dictionary.](https://www.center-tbi.eu/data/dictionary)

219

220 **Table 2. Variable count per category and subtype**

221 Data represent the number of subtype (*column*) variables per category (*row*).

222 Abbreviations: CSF=cerebrospinal fluid, ER=emergency room, ICU=intensive care unit, SBP=systolic blood

223 pressure, TBI=traumatic brain injury, UCH-L1=ubiquitin carboxy-terminal hydrolase L1.

224

²²⁵ *TILTomorrow modelling strategy*

 Whilst strong predictors of functional outcome after TBI are known, this is not the case for TIL. Thus, the TILTomorrow modelling strategy was designed to include *all* static and dynamic variables from CENTER-TBI to produce an evolving prediction of the next 230 calendar day's TIL^(Basic) over each patient's ICU stay. The large number of variables precludes building such a model by manual feature extraction, motivating our flexible tokenisation-and-embedding approach with no constraints on the number or type of variables per patient. We trained models, through supervised machine learning, with three 234 main components based on our prior studies^{13,15,19}: (1) a token-embedding encoder, (2) a gated recurrent neural network (RNN), and (3) an ordinal endpoint output layer. We created 100 partitions of our patient population for repeated *k*-fold cross-validation (20 repeats, 5 folds) with 15% of each training set randomly set aside as an internal validation set.

 ICU stays were partitioned into non-overlapping time windows, one per calendar day (Fig. 1a). Static variables were carried forward across all windows (Fig. 1b). All variables were tokenised through one of the following methods: (1) for categorical variables, appending the value to the variable name, (2) for numerical variables, learning the training set distribution and discretising into 20 quantile bins, (3) for text-based entries, removing all special characters, spaces, and capitalisation from the text and appending to the variable name, and (4) for missing values, creating a separate token to designate missingness (Fig. 1b). We selected 20 quantile bins for discretisation based on optimal performance 248 in our previous work.^{13,19} By labelling missing values with separate tokens instead of imputing them, the models could learn potentially significant patterns of missingness and integrate a diverse range of missing data without needing to validate the assumptions of 251 imputation methods on each variable.²⁰ During training, the models learned a low- dimensional vector (of either 128, 256, 512, or 1,024 units) and a 'relevance' weight for each token in the training set. Therefore, models would take the unique tokens from each time window of a patient, replace them with the corresponding vectors, and average the vectors – each weighted by its corresponding relevance score – into a single vector per time window (Fig. 1b).

 Each patient's sequence of low-dimensional vectors then fed into a gated RNN – either a long short-term memory (LSTM) network or a gated recurrent unit (GRU) – to output another vector per time window. In this manner, the models learned temporal patterns of variable interactions from training set ICU records and updated outputs with each new time window of data. Finally, each RNN output vector was decoded with a multinomial 263 (i.e., softmax) output layer to return a probability at each threshold of next-day TIL^(Basic) 264 over time (Fig. 1b). From these outputs, we also calculated the probabilities of TIL^(Basic) decreasing, staying the same, or increasing tomorrow in relation to the last available TIL^(Basic) score (Supplementary Methods S1). Please note that both threshold-level 267 probability estimates and estimated probabilities of next-day changes in $TIL^{(Basic)}$ are derived from the outputs of the same model, as described in Supplementary Methods S1.

 The combinations of hyperparameters – in addition to those already mentioned (embedding vector dimension and RNN type) – and the process of their optimisation in the internal validation sets are reported in Supplementary Methods S2–S3.

Model and information evaluation

 All metrics, curves, and associated confidence intervals (CIs) were calculated on the testing sets using the repeated Bootstrap Bias Corrected Cross-Validation (BBC-CV) 278 method, as described in Supplementary Methods S2. We calculated metrics and CIs at each day directly preceding a day of TIL assessment in our study population (i.e., days 1–6, 9, 13, 20, and 27).

 The reliability of model-generated prediction trajectories was assessed through the 283 calibration of output probabilities at each threshold of next-day TIL^(Basic). Using the logistic recalibration framework, 22 we first measured calibration slope. Calibration slope 285 less(/greater) than one indicates overfitting(/underfitting).²² Additionally, we examined smoothed probability calibration curves to detect miscalibrations that might have been 287 overlooked by the logistic recalibration framework.²²

 To evaluate prediction discrimination performance, we calculated the area under the 290 receiver operating characteristic curve (AUC) at each threshold of next-day $TL^{(Basic)}$. These AUCs are interpreted as the probability of the model correctly discriminating a 292 patient whose next-day TIL^(Basic) is above a given threshold from one with next-day 293 TIL^(Basic) below. Moreover, we calculated the AUC for prediction of next-day escalation 294 and de-escalation in TIL^(Basic). In this case, the AUC represents the probability of the model correctly discriminating a patient who experienced a day-to-day (de-)escalation in 296 $TIL^(Basic)$ from one who did not.

 We also assessed the information quality achieved by the combination of our modelling 299 strategy and the CENTER-TBI variables in predicting next-day changes in TIL^(Basic) by 300 calculating Somers' D_{xy} ²³ In our context, Somers' D_{xy} is interpreted as the proportion of 301 ordinal variation in day-to-day changes of TIL^(Basic) that is explained by the variation in 302 model output.²⁴ The calculation of Somers' D_{xy} is detailed in Supplementary Methods S4.

 We compared the performance of the TILTomorrow modelling strategy trained on the following factors to test their differential contribution to prediction: (1) the full variable set [2,008 variables], (2) all variables excluding physician-based impressions and treatments (e.g., all variables related to TIL) [1,803 variables], and (3) only static variables repeated in each time window [1,029 variables]. Our rationale for these ablated variable sets was to estimate the extent to which: (1) predictable trajectories of care – independent of other measured factors – influence treatment planning and (2) ICP treatments are responding to recorded events that occur over a patient's ICU stay. To serve as our reference for model comparison, we also calculated the performance achieved by simply carrying over 313 the last available TIL^(Basic) for prediction of next-day TIL^(Basic). This reference performance 314 accounts not only for the proportion of the population that did not change in TIL^(Basic) on a given day but also for the change in the assessment population caused by patient discharge over time.

Contributors to transitions in TIL

 We applied the TimeSHAP algorithm²⁵ on testing set predictions to find specific variables 321 associated with next-day changes in TIL^(Basic). TimeSHAP is a temporal extension of the 322 kernel-weighted SHapley Additive exPlanations (KernelSHAP) algorithm, ²⁶ which 323 estimates the relative contribution (i.e., Shapley value²⁷) of each model input to a specific patient's model output. In our case, this was done by masking sampled combinations of 325 tokens (i.e., coalitions) leading up to a patient's next-day change in TIL^(Basic) and calculating the difference in trained model output for each combination. A kernel-weighted linear regression model was then fit between binary coalition masks and resulting model outputs to estimate the Shapley value for each model input. TimeSHAP extends KernelSHAP by considering each unique combination of tokens and time windows as its own feature. Crucially, TimeSHAP made this computationally tractable for our application, in which models contain many possible tokens, by grouping low-contributing time windows in the distant past together as a single feature (i.e., temporal coalition pruning). TimeSHAP, KernelSHAP, and Shapley values are described in greater, mathematical detail in Supplementary Methods S5.

 We estimated token-level Shapley values with the TimeSHAP algorithm at both one day 337 and two days before an upcoming change in TIL^(Basic). Our chosen model output for 338 TimeSHAP was the expected next-day TIL^(Basic) score, as defined in Supplementary Methods S5. We then calculated the difference between the estimated Shapley values of 340 the two consecutive days for each token to derive its Δ TimeSHAP value. If a token did not exist in the window of either of the two days, then its Shapley value for that day was zero. Therefore, ΔTimeSHAP values were interpreted as the contributions of variable 343 tokens towards the difference in model prediction of next-day TIL^(Basic) over the two days 344 directly preceding the change in TIL^(Basic), given the patient's full set of tokens. If a variable had a positive (or negative) ΔTimeSHAP value, it was associated with an increased likelihood of escalation (or de-escalation) in next-day treatment intensity. Moreover, since the calculation of ΔTimeSHAP values required two days of information before the change 348 in TIL^(Basic), we only calculated the variable contributions to day-to-day changes in TIL^(Basic) that occurred after day two of ICU stay.

Results

Study population

 Of the 4,509 patients available for analysis in the CENTER-TBI core study, 844 patients from 51 ICUs met the inclusion criteria of this work (Supplementary Fig. S1). The median ICU stay duration of our population was 14 days (*Q*1–*Q*3: 8.4–23 days) and 86% (*n*=722) 358 stayed through at least seven calendar days. Since the regularity of TIL^(Basic) assessments decreased substantially after 14 days, and since less than half of the population remained in the ICU for 21 days (Supplementary Fig. S2), we focused our analysis on the first 14 days of ICU stay. Summary characteristics of the overall population as well as those 362 stratified by whether patients had a day-to-day change in $TIL^(Basic)$ over their first week in

 the ICU are detailed in Table 3. On average, patients who did not experience a change 364 in TIL^(Basic) over their first week were significantly younger, had higher baseline ICP values, and resulted in poorer functional recovery at six months post-injury (Table 3). However, their mean ICU stay duration was not significantly different.

367

370 Data are median (*Q*1–*Q*3) for numerical characteristics and *n* (% of column group) for categorical

371 characteristics unless otherwise indicated. Units or numerical definitions of characteristics are provided in 372 square brackets.

373 *Limited sample size of non-missing values for characteristic.

374 †Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical 375 information in the first 24 hours of ICU stay, as described previously.¹⁵

376 ⁺p-values, comparing patients who experienced a day-to-day change in TIL^(Basic) in the first week of ICU

377 stay to those who did not, are derived from Welch's *t*-test for numeric variables and *χ*² contingency table

378 test for categorical variables.

 Abbreviations: CT=Computerised tomography, GOSE=Glasgow Outcome Scale–Extended, GR=good recovery, ICP=intracranial pressure, ICU=intensive care unit, MD=moderate disability, Pr(GOSE>•)="probability of GOSE greater than • at six months post-injury" as previously calculated from 382 the first 24 hours of admission, 27 SD=severe disability, TIL=Therapy Intensity Level scale, 383 TIL^(Basic)=condensed TIL scale as measured in Table 1 for each calendar day, TIL^(Basic)_{median}=median TIL^(Basic) over first week of ICU stay.

385

386 The representation of each ICP-targeting treatment and $TIL^{(Basic)}$ score in our study is listed in Table 1. The least-represented treatment (higher-dose mannitol) was administered to 45 patients (5.3%) across 22 ICUs, whereas the least-represented $THL^{(Basic)}$ score (TIL^(Basic)=1) applied to 344 patients (41%) across 47 ICUs. A decompressive craniectomy for refractory intracranial hypertension was performed in 76 patients (9.0%) across 29 ICUs, and the median timepoint for such an operation was day 392 three $(Q_1-Q_3: two-five)$ of ICU stay.

393

394 The distribution of TIL^(Basic) values at each day of TIL assessment and the transitions of 395 TIL^(Basic) scores between days of assessment are visualised in Fig. 2a. No more than 2.4% 396 of the population's TIL^(Basic) scores were missing at any given assessment day, and the proportion of patients receiving basic-to-no ICP-targeting treatment (i.e., TIL^(Basic) \leq 1) 398 increased over time (Supplementary Fig. S2). The distribution of day-to-day changes in 399 TIL^(Basic) (Fig. 2b) demonstrates that there was considerably more change in TIL^(Basic) from 400 day one to day two than there was in any other pair of consecutive days. On the rest of 401 the days in the first week, 69–75% of the population did not experience a change in 402 TIL^(Basic) from one day to the next (Fig. 2b). The distribution of next-day TIL^(Basic) given the 403 current day's TIL^(Basic) (Supplementary Fig. S3) show that at least 79% of day-to-day 404 therapeutic transitions happen within one TIL^(Basic) category, except for escalations from 405 TIL^(Basic)=0 and de-escalations from TIL^(Basic)=4 from day one to two. When a change in 406 TIL^(Basic) did occur, the distributions of TIL^(Basic) before and after the change 407 (Supplementary Fig. S4) reflect a gradual trend towards de-escalation at later days of ICU 408 stay as expected.

WLST or Died Discharged

411 Fig. 2. Distributions of TIL^(Basic) and its day-to-day changes in the study population. (a) Alluvial 412 diagram of the evolution of the TIL^(Basic) distribution in the study population over the assessed days of ICU 413 stay. Percentages which round to 2% or lower are not shown. (**b**) Distributions of day-to-day changes in 414 TIL^(Basic). The numbers above each bar represent the number of study patients remaining in the ICU after 415 the corresponding day-to-day step. Percentages which round to 2% or lower are not shown. Abbreviations: 416 ICU=intensive care unit, TIL=Therapy Intensity Level, TIL^(Basic) = condensed, five-category TIL scale as 417 defined in Table 1, WLST=withdrawal of life-sustaining therapies.

418

⁴¹⁹ *Reliability and performance of TILTomorrow*

420

421 With both calibration slopes (Fig. 1c) and smoothed calibration curves (Fig. 1d) across 422 the thresholds of next-day TIL^(Basic), we observed that the TILTomorrow modelling strategy 423 achieved sufficient testing set calibration for analysis from day two of ICU stay onwards. 424 The 95% CI of the calibration slope pertaining to prediction of next-day TIL^(Basic) > 0 was 425 wider than that of other thresholds but still centred around a well-calibrated slope of one. 426

 In the first week of ICU stay, TILTomorrow correctly discriminated patients at each 428 threshold of next-day TIL^(Basic) between 79% (95% CI: 77–82%) and 95% (95% CI: 93– 96%) of the time (Fig. 3a). However, this apparently strong predictive power was in fact 430 Iargely because TIL^(Basic) tended not to change greatly (i.e., the "inertia" of TIL) across 431 day-to-day steps (Fig. 2b), especially at higher thresholds of next-day TIL^(Basic) (violet lines in Fig. 3a). After removing all treatments and physician-based impressions from the model variable set (including all variables related to TIL), the first-week AUCs dropped to between 0.65 (95% CI: 0.62–0.68) and 0.86 (95% CI: 0.82–0.89) with significantly lower 435 performance at higher thresholds of next-day $TIL^{(Basic)}$ (Fig. 3a). Models trained with only static variables achieved only marginally better discrimination than an uninformative predictor (best AUC: 0.60 [95% CI: 0.56–0.63], Fig. 3a).

Model variable set Full Only last available TIL^(Basic) No treatments ON odynamic

Fig. 3. Differential performance in discriminating and explaining next-day TIL(Basic) 440 **.** All shaded regions 441 surrounding curves and error bars are 95% confidence intervals derived using bias-corrected bootstrapping 442 (1,000 resamples) to represent the variation across 20 repeated five-fold cross-validation partitions. (**a**) 443 – Discrimination performance in prediction of next-day TIL^(Basic) – measured by AUC at each threshold of 444 TIL^(Basic) – by models trained on different variable sets. The violet line represents the performance achieved by simply carrying the last available TIL^(Basic) forward to account for the effect of day-to-day stasis in TIL^(Basic) 446 on prediction. The horizontal dashed line (AUC=0.5) represents the performance of uninformative prediction. (**b**) Discrimination performance in prediction of next-day de-escalation or escalation in TIL^(Basic)
448 – measured by AUC – by models trained on different variable sets. The horizontal dashed line (AUC=0.5) 448 – measured by AUC – by models trained on different variable sets. The horizontal dashed line (AUC=0.5) 449 represents the performance of uninformative prediction. (**c**) Explanation of ordinal variation in next-day 450 changes in TIL^(Basic) – measured by Somers' D_{xy} – by models trained on different variable sets. 451 Abbreviations: AUC=area under the receiver operating characteristic (ROC) curve, ICU=intensive care unit, 452 TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1.

453

454 To completely account for the inertia of TIL^(Basic) across day-to-day steps, we calculated 455 discrimination performance in the prediction of changes in next-day $TL^{(Basic)}$ (Fig. 3b). 456 Prediction performance was highest on day one across all variable sets, with the full-457 variable model correctly discriminating next-day de-escalations 90% (95% CI: 88–91%) 458 of the time and next-day escalations 85% (95% CI: 83–87%) of the time. Within each 459 variable set, change-in-TIL^(Basic) prediction performance did not change significantly from 460 day two onwards, except for the prediction of next-day escalation from static variables. 461 Treatment and physician-based impression variables significantly improved performance 462 in prediction of next-day de-escalations in TIL^(Basic) but not in prediction of next-day 463 escalations in TIL^(Basic) (Fig. 3b). Moreover, static variables achieved greater

464 discrimination in the prediction of TIL^(Basic) escalations than in the prediction of TIL^(Basic) de-escalations from days two to four of ICU stay.

-
-

Differential explanation of next-day changes in TIL

 The full set of 2,008 variables explained 68% (95% CI: 65–72%) of the ordinal variation 470 in next-day changes in TIL^(Basic) on day one and up to 51% (95% CI: 45–56%) through the rest of the first week (Fig. 3c). For the same endpoint, the 1,803 variables which exclude treatments and physician-based impressions explained 60% (95% CI: 57–64%) of the ordinal variation on day one and up to 35% (95% CI: 30–41%) thereafter (Fig. 3c). From Fig. 3b, we found that the explanation added from the prior trajectory of ICU management related more to informative patterns of treatment de-escalation than to those of escalation. At the same time, most of the explanation achieved by the full variable model could also be achieved without explicit information about the patient's treatments. The 1,029 static variables explained 54% (95% CI: 50–57%) of the ordinal variation in next-479 day changes in TIL^(Basic) on day one and decreased in explanation significantly from days two (28% [95% CI: 23–33%]) to six (13% [95% CI: 7–19%]) (Fig. 3c). In other words, the explanatory impact of dynamic variables increased over time in the ICU. Most of the explanatory information in static variables contributed towards prediction of treatment escalations earlier in patients' ICU stays (Fig. 3b).

Variables associated with next-day changes in TIL

 During the days of consecutive TIL assessment that were eligible for ΔTimeSHAP calculation (days 2–7), 575 patients (68% of population) experienced a total of 1,004 day-489 to-day changes in TIL^(Basic). The associative contributions of highest-impact variables towards prediction of these changes – both for models trained on all variables and for those trained without treatment variables – are visualised in Fig. 4. The number of points for each variable in Fig. 4 equals the number of times each variable was represented 493 across the 1,004 changes in TIL^(Basic). Moreover, we annotated several specific values of categorical variables in Fig. 4 because of their visually consistent association with next-495 day TIL^(Basic) de-escalation (i.e., negative ΔTimeSHAP) or TIL^(Basic) escalation (i.e., 496 positive Δ TimeSHAP). Across the leading predictors of next-day changes in TIL^(Basic) (Fig. 4), we found the following categories of variables:

- the preceding trajectory of ICU management (e.g., extubation, prior trajectory of TIL, ending nasogastric feeding),
- age at admission,
- bleeding risk factors (e.g., history of taking anticoagulants, baseline platelet count),
- brain imaging results (e.g., traumatic subarachnoid haemorrhage, subdural haematoma, intraparenchymal haemorrhage),
- haemodynamics and intracranial hypertension (e.g., ICP, blood pressure, respiratory efficiency),
- markers of systemic inflammation (e.g., ventilator-associated pneumonia [which may also reflect long ventilation time], eosinophils),
- metabolic derangements (e.g., sodium, calcium, alanine aminotransferase),

- 509 neurological function (e.g., Glasgow Coma Scale [GCS] eye and motor scores),
- 510 protein biomarkers (e.g., neurofilament-light chain, total tau protein).
- 511
-

512
513 **Fig 4. Population-level variable contributions to prediction of changes in next-day TIL^(Basic) at days directly preceding a change in TIL(Basic)** 514 **.** The ΔTimeSHAP values on the left panel are from the models 515 trained on the full variable set whilst the ΔTimeSHAP values on the right panel are from the models trained 516 without clinician impressions or treatments. ΔTimeSHAP values are interpreted as the relative contributions 517 of variables towards the difference in model prediction of next-day TIL^(Basic) over the two days directly 518 preceding the change in TIL^(Basic) (Supplementary Methods S5). Therefore, the study population 519 represented in this figure is limited to patients who experienced a change in TIL(Basic) after day two of ICU 520 stay (*n* = 575). A positive ΔTimeSHAP value signifies association with an increased likelihood of escalation 521 in next-day TIL^(Basic), whereas a negative ΔTimeSHAP value signifies association with an increased 522 likelihood of de-escalation. The variables were selected by first identifying the ten variables with non-523 missing value tokens with the most negative median ΔTimeSHAP values across the population (above the 524 ellipses) and then, amongst the remaining variables, selecting the ten with non-missing value tokens with 525 the most positive median ΔTimeSHAP values (below the ellipses). Each point represents the mean 526 ΔTimeSHAP value, taken across all 20 repeated cross-validation partitions, for a token preceding an 527 individual patient's change in TIL^(Basic). The number of points for each variable, therefore, indicates the 528 relative occurrence of that variable before changes in TIL(Basic) in the study population. The colour of the 529 point represents the relative ordered value of a token within a variable, and for unordered variables (e.g., 530 patient status during GCS assessment), tokens were sorted alphanumerically (the sort index per possible 531 unordered variable token is provided in the CENTER-TBI data dictionary: [https://www.center-](https://www.center-tbi.eu/data/dictionary)532 [tbi.eu/data/dictionary\)](https://www.center-tbi.eu/data/dictionary). Abbreviations: CVDs=cardiovascular diseases, ER=emergency room, F*I*O2=fraction 533 of inspired oxygen, GCS=Glasgow Coma Scale, ICP=intracranial pressure, P_aO₂=partial pressure of

534 oxygen, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1, VAP=ventilator-associated pneumonia.

537 The most robust predictors of next-day de-escalation in TIL $(Basic)$ were other clinical indicators of treatment de-escalation (e.g., ending nasogastric feeding), improvement in patients' eye-opening responses, previous administration of barbiturates or propofol, and 540 sufficient control of ICP. Overall, the effects of predictors for TIL^(Basic) escalation were not as robust as those for de-escalation (Fig. 4); however, stratifying the ΔTimeSHAP values by the pre-transition TIL^(Basic) score revealed more consistent associations per level of treatment intensity (Supplementary Fig. S5). For example, high ICP values were robustly 544 predictive of escalations from $\text{TL}^{(Basic)}=2$, and the prior administration of certain therapies 545 could be predictive of a future escalation or de-escalation based on the current $TIL^{(Basic)}$ score (Supplementary Fig. S5). Apart from treatment variables, the factors that contributed the most towards prediction of de-escalation from extreme ICP management (i.e., TIL^(Basic) = 4) were neurological improvements in motor and eye response with sufficiently controlled ICP and high blood oxygen saturation (Supplementary Fig. S5). The ΔTimeSHAP values of missing variables (Supplementary Fig. S6) demonstrated that missingness of a variable (e.g., missing report of daily complications) could have a significant de-escalating associative effect on model output.

Conceptual model of changes in treatment intensity

556 We combined the results from the differential explanation of next-day changes in TIL^(Basic) (Fig. 3b–c) and the variable contributions towards prediction of these events (Fig. 4) to produce a conceptual model of day-to-day changes in treatment intensity (Fig. 5). Given the considerable difference in explanation performance between day one and subsequent days of ICU stay, we separated these explanation percentages in our model.

562
563

 Fig 5. Conceptual diagram of factors explaining day-to-day changes in therapeutic intensity. The 564 percentage values represent the differential explanation of ordinal variation in next-day changes in TIL^(Basic) as measured by Somers' *Dxy*. The bolded percentage values represent the 95% confidence interval of Somers' *Dxy* from days 2–6 of ICU stay, whilst the percentage values below them represent the 95% confidence interval of Somers' *Dxy* from day 1 of ICU stay (Fig. 3c). The 95% confidence intervals were derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across 20 repeated five-fold cross-validation partitions. The leading static and dynamic pathophysiological factors were determined by qualitative categorisation of the variables with the highest contribution to next-day changes 571 in TIL^(Basic) based on ΔTimeSHAP values (Fig. 4). Abbreviations: TIL=Therapy Intensity Level, 572 TIL^(Basic) = condensed, five-category TIL scale as defined in Table 1.

573

⁵⁷⁴ **Discussion**

575

576 We present the first approach to dynamic prediction of future therapy intensity levels (TIL) 577 in ICP-monitored TBI patients. The TILTomorrow modelling strategy allowed us to exploit 578 the full clinical context (2,008 variables) captured in a large neurotrauma dataset over 579 time to uncover factors associated with next-day changes in $TIL^(Basic).¹⁹$ By including 580 missing value tokens, models discovered meaningful patterns of missingness 581 (Supplementary Fig. S6).²⁰ Moreover, our approach mapped clinical events to evolving 582 predictions at each ordinal level of next-day TIL^(Basic), which is an improvement in 583 statistical power and clinical information over using a dichotomised measure of 584 therapeutic intensity (e.g., high-TIL therapies).¹⁵

585

586 The main results of this study are summarised in the conceptual diagram of changes in 587 TIL^(Basic) (Fig. 5). Amongst all day-to-day steps, the transition from day one to day two had 588 the greatest number of changes in TIL^(Basic) (Fig. 2b), which were also the most predictable (68% [95% CI: 65–72%] explanation, Fig. 3c). From day two onwards, the ordinal 590 explanation of changes in next-day TIL^(Basic) dropped to between 39% (95% CI: 32–47%) and 51% (95% CI: 45–56%). This difference suggests that first-to-second-day changes in treatment intensity might have been the most systematic, possibly associated with primary injury severity and initial patient responses to treatment (Fig. 3c). Later in ICU stay, the predictive influence of a patient's treatment trajectory increased (mostly through informative patterns of de-escalation, Fig. 3b), and that of static factors decreased (Fig. 596 3c). Whilst static factors are poor predictors of TIL^(Basic) on any given day (Fig. 3a and as shown previously¹²), they achieve considerable discrimination performance in prediction of escalations up to day four (AUC: 0.70 [95% CI: 0.65–0.74], Fig. 3b). This may indicate the potential of certain primary injury factors for justifying earlier intervention as to avoid tolerating suboptimal ICP management for a few days. Apart from age, the highest- contributing static factors were space-occupying lesions (also reflected in a recent 602 study²⁸) and bleeding risk factors (Fig. 4), both of which can complicate ICP control. As targets of TIL therapies, ICP and haemodynamic factors are expectedly high-contributing, 604 with different effects based on the pre-transition $TIL^{(Basic)}$ score (Supplementary Fig. S5). Metabolic complications (i.e., abnormalities in renal or liver function and electrolytic imbalances) have previously been shown to be significantly more common in patients 607 receiving high-TIL therapies¹² and an important marker for physiological endotyping.²⁹ Moreover, in a prior study, serial protein biomarkers (in addition to GCS) were key 609 descriptors for clustering TBI patient trajectories in the ICU.³⁰ Therefore, the results from these dynamic variables support the links between TIL and pathophysiology – including 611 systemic factors (e.g., metabolism and inflammation) – after TBI.⁷ This is potentially of clinical importance since protein biomarkers are not measured serially as part of typical routine care outside of research studies (e.g., CENTER-TBI) and a few centres. It is still uncertain whether serial biomarker measurement would improve care outcomes. However, analysing the temporal dynamics of these biomarkers may not only enable a more precise characterisation of patients' treatment needs but also elucidate biological mechanisms underpinning variable treatment response. Finally, whilst we found no significant difference in full-model prediction performance between next-day escalations 619 and de-escalations of TIL^(Basic) (Fig. 3b), high-impact predictors had a more robust signal with de-escalations than they did with escalations (i.e., more consistently negative ΔTimeSHAP values in Fig. 4). This suggests that escalation prediction may be the effect of a complex interaction of factors which is difficult to perceive with ΔTimeSHAP values.

 The underlying assumption of this work is that a more protocolised management of ICP would also be more predictable based on the dynamic condition of a TBI patient. Even 626 with wide inter-centre variation in ICP-targeting treatment,¹⁴ we would expect the measurable factors which rationally drive day-to-day changes in TIL to predict such changes on an individual level. After day two, approximately half of the ordinal variation 629 in day-to-day changes in TIL^(Basic) is unexplained by the full CENTER-TBI variable set, and we propose four reasons for this remaining uncertainty (Fig. 5). First, certain clinical events or complications that could suddenly trigger a (de-)escalation in TIL (e.g., sustained rise in ICP) might not have been predictable from the day before. Second, there are probably important physiological factors, either unmeasured or not included in our

 variable set, which would have improved TIL prediction. Most notably, high-resolution 635 waveforms of $ICP³¹$ and arterial blood pressure (ABP) and their derived metrics (e.g., 636 pressure-time dose³² and vascular reactivity³³) are more likely to elucidate ICP management decisions than the bihourly clinician-recorded ICP or CPP values available 638 in our variable set.³⁴ Prior analyses of additional physiological modalities – e.g., cerebral 639 microdialysis, automated pupillometry, $36,37$ and motion sensing 38 – have also demonstrated independent associations with TIL or other short-term endpoints after TBI. Third, assuming different centres have different protocols for ICP management, there may not have been enough patient representation across the spectrum of TBI severity from each centre for TILTomorrow to learn centre-specific guidelines. Fourth, a part of ICP management may be driven by the personal preferences of clinicians in deviation from general guidelines. At the same time, we recognise that predictability does not guarantee a systematised delivery of care. We therefore investigated differential explanation of (Fig. 3b–c) and specific variable contributions towards (Fig. 4) changes in TIL to bridge prediction performance to a plausible concept of ICP management (Fig. 5).

650 Our results support the use of TIL as an intermediate outcome after TBI.⁷ Specific categories of pathophysiological variables – both static and dynamic – associate well with changes in TIL (Fig. 4 and 5). Since TIL rates the relative risk and complexity of administered treatments, it is logical to minimise TIL when all other factors are held equal. On the other hand, TIL is also a complicated marker of pathophysiology. Since around half of the ordinal variation in changes in TIL is not explained by measured variables (Fig. 5), we hypothesise that TIL's sensitivity to pathophysiology is partially confounded by the personal preferences of clinical teams. Nevertheless, TIL was previously shown to be a stronger indicator of refractory intracranial hypertension than ICP itself and, thus, a more 659 suitable intermediate endpoint for TBI management.⁷ Since the full information pertaining to TIL was only date-stamped in CENTER-TBI, the highest resolution at which we could 661 assess TIL^(Basic) was once per calendar day (Table 1). However, clinicians were also asked to record qualitatively whether treatment intensity was decreasing or increasing 663 every four hours, and these indications (from the day before a change in TIL^(Basic)) were 664 amongst the strongest predictors of next-day changes in $TIL^{(Basic)}$ (Fig. 4). This result supports a higher resolution TIL for monitoring pathophysiological severity; however, daily 666 TIL scores have been shown to be reliable estimates of hourly TIL scores, ⁹ and CENTER- TBI has demonstrated the practical feasibility of daily TIL assessment for a large-scale study (≤2.4% missingness, Fig. 2a).

 TILTomorrow can potentially be useful in other heterogeneous-data-intensive clinical domains as a framework for decoding factors tied to treatment decision-making or other dynamic endpoints. This can inform the design of future causal inference models of 673 individualised treatment effects from observational data.³⁹ TILTomorrow was not conceived for clinical deployment and should not be used for real-time decision support 675 due to concerns of self-fulfilling prophecies, generalisability, and variable robustness. 40 Our focus was on explanatory modelling, to derive insightful patterns from the CENTER- TBI data and quantify the predictability of ICP management. Furthermore, ΔTimeSHAP values on observational data are merely associative and cannot be interpreted for causal inference. We used TimeSHAP in this work to highlight potential areas of investigation

 from a wider, data-driven approach. Pathophysiological predictors of the need for higher TIL (Fig. 4 and 5) could be useful for improving the timing and precision of future clinical decision-making (e.g., performing decompressive craniectomy in a timely but targeted way) but would require more evidence and feasibility studies than just their predictive power in our data.

 We recognise several additional limitations in this study. TILTomorrow discretised both numerical variables into binned tokens and time into daily windows, which caused some loss of information. Limited by the resolution of available TIL assessments, we chose a daily time window to avoid inconsistent lead times in our prediction task (Fig. 1a). The highest resolution of regularly recorded variables (e.g., ICP) in the CENTER-TBI core 691 study is once every two hours, and, since TILTomorrow takes the unique set of tokens per daily window prior to embedding, these numerical variables would be reduced to the unique set of quantiles represented in a day (Fig. 1b). An encoding strategy which can integrate high-resolution ICP, CPP, and other clinical information into broader time 695 windows may improve prediction performance. Additionally, the daily TIL^(Basic) score 696 accounts for 33% of the information in the full, 38-point TIL score.⁷ As explained in the 697 Methods, we used $TIL^{(Basic)}$ as the model endpoint over the full TIL score since it would enable us to uncover factors associated with changes across specific, interpretable bands of treatment intensity (Table 1). Nevertheless, a regression-based prediction of next-day full TIL may capture more nuanced patterns of factors associated with changes in ICP management. Finally, our results may encode recruitment, collection, and clinical biases native to our European patient set. Selective recording of clinical data – with selective missingness – may have biased our analyses, and findings may not generalise to other populations.⁴¹ Given the broad inter-centre variation in ICP-targeted care,¹⁴ the results of TILTomorrow are likely to vary considerably depending on the protocols of specific centres. We encourage investigators to apply the TILTomorrow approach to other longitudinal, granular ICU datasets of TBI patients – particularly in low- and middle- income countries where the burden of TBI is disproportionately higher⁴² – and compare their results.

Data and code availability

 Individual participant data, including data dictionary, the study protocol, and analysis scripts are available online, conditional to approved study proposal, with no end date. Interested investigators must submit a study proposal to the management committee at [https://www.center-tbi.eu/data.](https://www.center-tbi.eu/data) Signed confirmation of a data access agreement is required, and all access must comply with regulatory restrictions imposed on the original study.

 All code used in this project can be found at the following online repository: <https://github.com/sbhattacharyay/TILTomorrow> (DOI: 10.5281/zenodo.11060742).

- **Acknowledgments**
-

 This research was supported by the National Institute for Health Research (NIHR) Brain 726 Injury MedTech Co-operative. CENTER-TBI was supported by the European Union $7th$ Framework programme (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA), and from NeuroTrauma Sciences (USA). CENTER-TBI also acknowledges interactions and support from the International Initiative for TBI Research (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded by the Medical Research Council (MR N013433-1) and by a Gates Cambridge Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

735

736 We are grateful to the patients and families of our study for making our efforts to improve 737 TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University) 738 for offering comments on the manuscript.

739

⁷⁴⁰ **The CENTER-TBI investigators and participants**

741

742 The co-lead investigators of CENTER-TBI are designated with an asterisk (*), and their 743 contact email addresses are listed below.

744

745 Cecilia Åkerlund¹, Krisztina Amrein², Nada Andelic³, Lasse Andreassen⁴, Audny Anke⁵, 746 Anna Antoni⁶, Gérard Audibert⁷, Philippe Azouvi⁸, Maria Luisa Azzolini⁹, Ronald Bartels¹⁰, 747 Pál Barzó¹¹, Romuald Beauvais¹², Ronny Beer¹³, Bo-Michael Bellander¹⁴, Antonio Belli¹⁵, 748 Habib Benali¹⁶, Maurizio Berardino¹⁷, Luigi Beretta⁹, Morten Blaabjerg¹⁸, Peter Bragge¹⁹, 749 Alexandra Brazinova²⁰, Vibeke Brinck²¹, Joanne Brooker²², Camilla Brorsson²³, Andras 750 Buki²⁴, Monika Bullinger²⁵, Manuel Cabeleira²⁶, Alessio Caccioppola²⁷, Emiliana 751 Calappi²⁷, Maria Rosa Calvi⁹, Peter Cameron²⁸, Guillermo Carbayo Lozano²⁹, Marco 752 Carbonara²⁷, Simona Cavallo¹⁷, Giorgio Chevallard³⁰, Arturo Chieregato³⁰, Giuseppe 753 Citerio^{31,32}, Hans Clusmann³³, Mark Coburn³⁴, Jonathan Coles³⁵, Jamie D. Cooper³⁶, 754 Marta Correia³⁷, Amra Čović³⁸, Nicola Curry³⁹, Endre Czeiter²⁴, Marek Czosnyka²⁶, Claire 755 Dahyot-Fizelier⁴⁰, Paul Dark⁴¹, Helen Dawes⁴², Véronique De Keyser⁴³, Vincent Degos¹⁶, 756 Francesco Della Corte⁴⁴, Hugo den Boogert¹⁰, Bart Depreitere⁴⁵, Đula Đilvesi⁴⁶, Abhishek 757 Dixit⁴⁷, Emma Donoghue²², Jens Dreier⁴⁸, Guy-Loup Dulière⁴⁹, Ari Ercole⁴⁷, Patrick 758 Esser⁴², Erzsébet Ezer⁵⁰, Martin Fabricius⁵¹, Valery L. Feigin⁵², Kelly Foks⁵³, Shirin 759 Frisvold⁵⁴, Alex Furmanov⁵⁵, Pablo Gagliardo⁵⁶, Damien Galanaud¹⁶, Dashiell Gantner²⁸, 760 Guoyi Gao⁵⁷, Pradeep George⁵⁸, Alexandre Ghuysen⁵⁹, Lelde Giga⁶⁰, Ben Glocker⁶¹, 761 Jagoš Golubovic⁴⁶, Pedro A. Gomez⁶², Johannes Gratz⁶³, Benjamin Gravesteijn⁶⁴, 762 Francesca Grossi⁴⁴, Russell L. Gruen⁶⁵, Deepak Gupta⁶⁶, Juanita A. Haagsma⁶⁴, Iain 763 Haitsma⁶⁷, Raimund Helbok¹³, Eirik Helseth⁶⁸, Lindsay Horton⁶⁹, Jilske Huijben⁶⁴, Peter 764 J. Hutchinson⁷⁰, Bram Jacobs⁷¹, Stefan Jankowski⁷², Mike Jarrett²¹, Ji-yao Jiang⁵⁸, Faye 765 Johnson⁷³, Kelly Jones⁵², Mladen Karan⁴⁶, Angelos G. Kolias⁷⁰, Erwin Kompanje⁷⁴, Daniel 766 Kondziella⁵¹, Evgenios Kornaropoulos⁴⁷, Lars-Owe Koskinen⁷⁵, Noémi Kovács⁷⁶, Ana 767 Kowark⁷⁷, Alfonso Lagares⁶², Linda Lanyon⁵⁸, Steven Laureys⁷⁸, Fiona Lecky^{79,80}, Didier 768 Ledoux⁷⁸, Rolf Lefering⁸¹, Valerie Legrand⁸², Aurelie Lejeune⁸³, Leon Levi⁸⁴, Roger 769 Lightfoot⁸⁵, Hester Lingsma⁶⁴, Andrew I.R. Maas^{43,86,*}, Ana M. Castaño-León⁶², Marc 770 Maegele⁸⁷, Marek Majdan²⁰, Alex Manara⁸⁸, Geoffrey Manley⁸⁹, Costanza Martino⁹⁰,

771 Hugues Maréchal⁴⁹, Julia Mattern⁹¹, Catherine McMahon⁹², Béla Melegh⁹³, David
772 Menon^{47,}*, Tomas Menovsky^{43,86}, Ana Mikolic⁶⁴, Benoit Misset⁷⁸, Visakh 772 Menon^{47,*}, Tomas Menovsky^{43,86}, Ana Mikolic⁶⁴, Benoit Misset⁷⁸, Visakh 773 Muraleedharan⁵⁸, Lynnette Murray²⁸, Ancuta Negru⁹⁴, David Nelson¹, Virginia 774 Newcombe⁴⁷, Daan Nieboer⁶⁴, József Nyirádi², Otesile Olubukola⁷⁹, Matej Oresic⁹⁵, 775 Fabrizio Ortolano²⁷, Aarno Palotie^{96,97,98}, Paul M. Parizel⁹⁹, Jean-François Payen¹⁰⁰, 776 Natascha Perera¹², Vincent Perlbarg¹⁶, Paolo Persona¹⁰¹, Wilco Peul¹⁰², Anna Piippo-777 Karjalainen¹⁰³, Matti Pirinen⁹⁶, Dana Pisica⁶⁴, Horia Ples⁹⁴, Suzanne Polinder⁶⁴, Inigo 778 Pomposo²⁹, Jussi P. Posti¹⁰⁴, Louis Puybasset¹⁰⁵, Andreea Radoi¹⁰⁶, Arminas 779 Ragauskas¹⁰⁷, Rahul Raj¹⁰³, Malinka Rambadagalla¹⁰⁸, Isabel Retel Helmrich⁶⁴, Jonathan 780 Rhodes¹⁰⁹, Sylvia Richardson¹¹⁰, Sophie Richter⁴⁷, Samuli Ripatti⁹⁶, Saulius Rocka¹⁰⁷, 781 Cecilie Roe¹¹¹, Olav Roise^{112,113}, Jonathan Rosand¹¹⁴, Jeffrey V. Rosenfeld¹¹⁵, Christina 782 Rosenlund¹¹⁶, Guy Rosenthal⁵⁵, Rolf Rossaint⁷⁷, Sandra Rossi¹⁰¹, Daniel Rueckert⁶¹ 783 Martin Rusnák¹¹⁷, Juan Sahuquillo¹⁰⁶, Oliver Sakowitz^{91,118}, Renan Sanchez-Porras¹¹⁸, 784 Janos Sandor¹¹⁹, Nadine Schäfer⁸¹, Silke Schmidt¹²⁰, Herbert Schoechl¹²¹, Guus 785 Schoonman¹²², Rico Frederik Schou¹²³, Elisabeth Schwendenwein⁶, Charlie Sewalt⁶⁴, 786 Ranjit D. Singh¹⁰², Toril Skandsen^{124,125}, Peter Smielewski²⁶, Abayomi Sorinola¹²⁶, 787 Emmanuel Stamatakis⁴⁷, Simon Stanworth³⁹, Robert Stevens¹²⁷, William Stewart¹²⁸, 788 Ewout W. Steyerberg^{64,129}, Nino Stocchetti¹³⁰, Nina Sundström¹³¹, Riikka Takala¹³², 789 Viktória Tamás¹²⁶, Tomas Tamosuitis¹³³, Mark Steven Taylor²⁰, Aurore Thibaut⁷⁸, Braden 790 Te Ao⁵², Olli Tenovuo¹⁰⁴, Alice Theadom⁵², Matt Thomas⁸⁸, Dick Tibboel¹³⁴, Marjolein 791 Timmers⁷⁴, Christos Tolias¹³⁵, Tony Trapani²⁸, Cristina Maria Tudora⁹⁴, Andreas 792 Unterberg⁹¹, Peter Vajkoczy¹³⁶, Shirley Vallance²⁸, Egils Valeinis⁶⁰, Zoltán Vámos⁵⁰, 793 Mathieu van der Jagt¹³⁷, Gregory Van der Steen⁴³, Joukje van der Naalt⁷¹, Jeroen T.J.M. 794 van Dijck¹⁰², Inge A. M. van Erp¹⁰², Thomas A. van Essen¹⁰², Wim Van Hecke¹³⁸, Caroline 795 van Heugten¹³⁹, Ernest van Veen⁶⁴, Thijs Vande Vyvere¹⁴⁰, Roel P. J. van Wijk¹⁰², Alessia 796 Vargiolu³², Emmanuel Vega⁸³, Kimberley Velt⁶⁴, Jan Verheyden¹³⁸, Paul M. Vespa¹⁴¹, 797 Anne Vik^{124,142}, Rimantas Vilcinis¹³³, Victor Volovici⁶⁷, Nicole von Steinbüchel³⁸, Daphne 798 Voormolen⁶⁴, Petar Vulekovic⁴⁶, Kevin K.W. Wang¹⁴³, Daniel Whitehouse⁴⁷, Eveline 799 Wiegers⁶⁴, Guy Williams⁴⁷, Lindsay Wilson⁶⁹, Stefan Winzeck⁴⁷, Stefan Wolf¹⁴⁴, Zhihui 800 Yang¹¹⁴, Peter Ylén¹⁴⁵, Alexander Younsi⁹¹, Frederick A. Zeiler^{47,146}, Veronika 801 Zelinkova²⁰, Agate Ziverte⁶⁰, Tommaso Zoerle²⁷

- 802
- 803 1Department of Physiology and Pharmacology, Section of Perioperative Medicine and 804 Intensive Care, Karolinska Institutet, Stockholm, Sweden
- 805 ² János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- 806 ³Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, 807 Oslo University Hospital and University of Oslo, Oslo, Norway
- 808 ⁴Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway
- 809 5Department of Physical Medicine and Rehabilitation, University Hospital Northern 810 Norway, Tromso, Norway
- 811 ⁶ Trauma Surgery, Medical University Vienna, Vienna, Austria
- 812 7Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, 813 France
- 814 ⁸Raymond Poincare hospital, Assistance Publique Hopitaux de Paris, Paris, France
- 815 9Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, 816 Italy

- 817 ¹⁰Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The 818 Netherlands
- 819 ¹¹Department of Neurosurgery, University of Szeged, Szeged, Hungary
- 820 ¹² International Projects Management, ARTTIC, Munchen, Germany
- 821 ¹³Department of Neurology, Neurological Intensive Care Unit, Medical University of 822 Innsbruck, Innsbruck, Austria
- 823 ¹⁴Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska 824 University Hospital, Stockholm, Sweden
- 825 ¹⁵NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- 826 ¹⁶ Anesthesie-Réanimation, Assistance Publique Hopitaux de Paris, Paris, France
- 827 17Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino 828 Orthopedic and Trauma Center, Torino, Italy
- 829 ¹⁸Department of Neurology, Odense University Hospital, Odense, Denmark
- 830 BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, 831 Australia
- 832 ²⁰Department of Public Health, Faculty of Health Sciences and Social Work, Trnava 833 University, Trnava, Slovakia
- 834 ²¹Quesgen Systems Inc., Burlingame, California, USA
- 835 ²² Australian & New Zealand Intensive Care Research Centre, Department of 836 Epidemiology and Preventive Medicine, School of Public Health and Preventive 837 Medicine, Monash University, Melbourne, Australia
- 838 ²³Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- 839 ²⁴Department of Neurosurgery, Medical School, University of Pécs, Hungary and 840 Neurotrauma Research Group, János Szentágothai Research Centre, University of 841 Pécs, Hungary
- 842 ²⁵Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, 843 Hamburg, Germany
- 844 ²⁶ Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University 845 of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- 846 ²⁷Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- 847 ²⁸ ANZIC Research Centre, Monash University, Department of Epidemiology and 848 Preventive Medicine, Melbourne, Victoria, Australia
- 849 ²⁹Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
- 850 ³⁰NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- 851 ³¹ School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
- 852 ³²NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo 853 dei Tintori, Monza, Italy
- 854 ³³Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, 855 Germany
- 856 ³⁴Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 857 Bonn, Germany
- 858 ³⁵Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS 859 Foundation Trust, Cambridge, UK
- 860 ³⁶ School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, 861 Victoria, Australia
- 862 ³⁷Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

863 ³⁸ Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, 864 Göttingen, Germany 865 ³⁹Oxford University Hospitals NHS Trust, Oxford, UK 866 ⁴⁰ Intensive Care Unit, CHU Poitiers, Potiers, France 867 41 University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, 868 Salford Royal Hospital NHS Foundation Trust, Salford, UK 869 ⁴²Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes 870 University, Oxford, UK 871 43Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium 872 ⁴⁴Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, 873 Italy 874 ⁴⁵Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium 875 ⁴⁶Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, 876 University of Novi Sad, Novi Sad, Serbia 877 ⁴⁷Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, 878 UK 879 ⁴⁸Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate 880 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute 881 of Health, Berlin, Germany 882 ⁴⁹ Intensive Care Unit, CHR Citadelle, Liège, Belgium 883 ⁵⁰Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, 884 Hungary 885 ⁵¹Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region 886 Hovedstaden Rigshospitalet, Copenhagen, Denmark 887 ⁵²National Institute for Stroke and Applied Neurosciences, Faculty of Health and 888 Environmental Studies, Auckland University of Technology, Auckland, New Zealand 889 ⁵³Department of Neurology, Erasmus MC, Rotterdam, the Netherlands 890 ⁵⁴Department of Anesthesiology and Intensive care, University Hospital Northern Norway, 891 Tromso, Norway 892 ⁵⁵Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, 893 Israel 894 ⁵⁶ Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain 895 57Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong 896 University/school of medicine, Shanghai, China 897 ⁵⁸ Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, 898 Stockholm, Sweden 899 ⁵⁹ Emergency Department, CHU, Liège, Belgium 900 60Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia 901 6¹Department of Computing, Imperial College London, London, UK 902 62Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain 903 ⁶³Department of Anesthesia, Critical Care and Pain Medicine, Medical University of 904 Vienna, Austria 905 64Department of Public Health, Erasmus Medical Center-University Medical Center, 906 Rotterdam, The Netherlands 907 ⁶⁵College of Health and Medicine, Australian National University, Canberra, Australia

- 908 ⁶⁶Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All 909 India Institute of Medical Sciences, New Delhi-110029, India
- 910 ⁶⁷Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- 911 ⁶⁸Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- 912 ⁶⁹Division of Psychology, University of Stirling, Stirling, UK
- 913 ⁷⁰Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's 914 Hospital & University of Cambridge, Cambridge, UK
- 915 ⁷¹Department of Neurology, University of Groningen, University Medical Center 916 Groningen, Groningen, Netherlands
- 917 ⁷²Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, 918 UK
- 919 ⁷³ Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, 920 UK
- 921 ⁷⁴Department of Intensive Care and Department of Ethics and Philosophy of Medicine, 922 Erasmus Medical Center, Rotterdam, The Netherlands
- 923 ⁷⁵Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- 924 ⁷⁶Hungarian Brain Research Program Grant No. KTIA 13 NAP-A-II/8, University of 925 Pécs, Pécs, Hungary
- 926 ⁷⁷Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- 927 ⁷⁸Cyclotron Research Center, University of Liège, Liège, Belgium
- 928 ⁷⁹ Centre for Urgent and Emergency Care Research (CURE), Health Services Research 929 Section, School of Health and Related Research (ScHARR), University of Sheffield, 930 Sheffield, UK
- 931 ⁸⁰ Emergency Department, Salford Royal Hospital, Salford UK
- 932 81 Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, 933 Cologne, Germany
- 934 82VP Global Project Management CNS, ICON, Paris, France
- 935 83Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- 936 84Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- 937 ⁸⁵Department of Anesthesiology & Intensive Care, University Hospitals Southhampton 938 NHS Trust, Southhampton, UK
- 939 ⁸⁶Department of Translational Neuroscience, Faculty of Medicine and Health Science, 940 University of Antwerp, Antwerp, Belgium
- 941 87Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic 942 Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- 943 88Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- 944 89Department of Neurological Surgery, University of California, San Francisco, California, 945 USA
- 946 ⁹⁰Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- 947 9⁹¹ Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- 948 92Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK
- 949 ⁹³Department of Medical Genetics, University of Pécs, Pécs, Hungary
- 950 94Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, 951 Romania
- 952 ⁹⁵ School of Medical Sciences, Örebro University, Örebro, Sweden
- 953 ⁹⁶ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

- 954 ⁹⁷ Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric & 955 Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of 956 Neurology, Massachusetts General Hospital, Boston, MA, USA
- 957 ⁹⁸ Program in Medical and Population Genetics; The Stanley Center for Psychiatric 958 Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 959 99Department of Radiology, University of Antwerp, Edegem, Belgium
- 960 ¹⁰⁰Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, 961 Grenoble, France
- 962 101Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di 963 Padova, Padova, Italy
- 964 ¹⁰²Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and 965 Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
- 966 ¹⁰³Department of Neurosurgery, Helsinki University Central Hospital
- 967 ¹⁰⁴Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury 968 Centre, Turku University Hospital and University of Turku, Turku, Finland
- 969 ¹⁰⁵Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital, 970 Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, 971 France
- 972 ¹⁰⁶Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron 973 Research Institute, Barcelona, Spain
- 974 ¹⁰⁷Department of Neurosurgery, Kaunas University of technology and Vilnius University, 975 Vilnius, Lithuania
- 976 ¹⁰⁸Department of Neurosurgery, Rezekne Hospital, Latvia
- 977 ¹⁰⁹Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University 978 of Edinburg, Edinburgh, UK
- 979 ¹¹⁰Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- 980 111Department of Physical Medicine and Rehabilitation, Oslo University 981 Hospital/University of Oslo, Oslo, Norway
- 982 112Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- 983 ¹¹³ Institue of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 984 ¹¹⁴ Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts 985 General Hospital, Boston MA, USA
- 986 ¹¹⁵National Trauma Research Institute, The Alfred Hospital, Monash University, 987 Melbourne, Victoria, Australia
- 988 116Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- 989 ¹¹⁷ International Neurotrauma Research Organisation, Vienna, Austria
- 990 ¹¹⁸ Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- 991 ¹¹⁹Division of Biostatistics and Epidemiology, Department of Preventive Medicine, 992 University of Debrecen, Debrecen, Hungary
- 993 ¹²⁰Department Health and Prevention, University Greifswald, Greifswald, Germany
- 994 ¹²¹Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, 995 Austria
- 996 ¹²²Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- 997 ¹²³Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, 998 Odense, Denmark

- 999 ¹²⁴Department of Neuromedicine and Movement Science, Norwegian University of 1000 Science and Technology, NTNU, Trondheim, Norway
- 1001 ¹²⁵Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim 1002 University Hospital, Trondheim, Norway
- 1003 ¹²⁶Department of Neurosurgery, University of Pécs, Pécs, Hungary
- 1004 ¹²⁷Division of Neuroscience Critical Care, John Hopkins University School of Medicine, 1005 Baltimore, USA
- 1006 ¹²⁸Department of Neuropathology, Queen Elizabeth University Hospital and University of 1007 Glasgow, Glasgow, UK
- 1008 ¹²⁹Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center, 1009 Leiden, The Netherlands
- 1010 ¹³⁰Department of Pathophysiology and Transplantation, Milan University, and 1011 Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 1012 Milano, Italy
- 1013 ¹³¹Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, 1014 Sweden
- 1015 ¹³² Perioperative Services, Intensive Care Medicine and Pain Management, Turku 1016 University Hospital and University of Turku, Turku, Finland
- 1017 133Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- 1018 ¹³⁴ Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia 1019 Children's Hospital, Rotterdam, The Netherlands
- 1020 ¹³⁵Department of Neurosurgery, Kings college London, London, UK
- 1021 136Neurologie, Neurochirurgie und Psychiatrie, Charité Universitätsmedizin Berlin, 1022 Berlin, Germany
- 1023 137Department of Intensive Care Adults, Erasmus MC– University Medical Center 1024 Rotterdam, Rotterdam, the Netherlands
- 1025 ¹³⁸ icoMetrix NV, Leuven, Belgium
- 1026 ¹³⁹Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes 1027 University, Oxford, UK
- 1028 140Radiology Department, Antwerp University Hospital, Edegem, Belgium
- 1029 141Director of Neurocritical Care, University of California, Los Angeles, USA
- 1030 142Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital, 1031 Trondheim, Norway
- 1032 ¹⁴³Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
- 1033 144Department of Neurosurgery, Charité Universitätsmedizin Berlin, corporate member 1034 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of 1035 Health, Berlin, Germany
- 1036 ¹⁴⁵ VTT Technical Research Centre, Tampere, Finland
- 1037 ¹⁴⁶ Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, 1038 University of Manitoba, Winnipeg, MB, Canada
- 1039
- 1040 *Co-lead investigators: andrew.maas@uza.be (AIRM) and dkm13@cam.ac.uk (DM)
- 1041

¹⁰⁴² **References**

- 1 Meyfroidt G, Bouzat P, Casaer MP, *et al.* Management of moderate to severe traumatic brain injury: an update for the intensivist. *Intensive Care Med* 2022; **48**: 649–66.
- 2 Maas AIR, Menon DK, Adelson PD, *et al.* Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017; **16**: 987–1048.
- 3 Maas AIR, Menon DK, Manley GT, *et al.* Traumatic brain injury: progress and challenges in prevention, clinical care, and research. *Lancet Neurol* 2022; **21**: 1004– 60.
- 4 Hawryluk GWJ, Aguilera S, Buki A, *et al.* A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). *Intensive Care Med* 2019; **45**: 1783–94.
- 5 Carney N, Totten AM, O'Reilly C, *et al.* Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017; **80**: 6.
- 6 Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. *N Engl J Med* 2014; **370**: 2121–30.
- 7 Bhattacharyay S, Beqiri E, Zuercher P, *et al.* Therapy Intensity Level Scale for Traumatic Brain Injury: Clinimetric Assessment on Neuro-Monitored Patients Across 52 European Intensive Care Units. *J Neurotrauma* 2024; **41**: 887–909.
- 8 Maas AIR, Harrison-Felix CL, Menon D, *et al.* Standardizing Data Collection in Traumatic Brain Injury. *J Neurotrauma* 2011; **28**: 177–87.
- 9 Zuercher P, Groen JL, Aries MJH, *et al.* Reliability and Validity of the Therapy Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to Assess Management of Intracranial Pressure in Traumatic Brain Injury. *J Neurotrauma* 2016; **33**: 1768–74.
- 10 Maas AIR, Menon DK, Steyerberg EW, *et al.* Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective Longitudinal Observational Study. *Neurosurgery* 2015; **76**: 67–80.
- 11 Steyerberg EW, Wiegers E, Sewalt C, *et al.* Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. *Lancet Neurol* 2019; **18**: 923–34.
- 12 Huijben JA, Dixit A, Stocchetti N, *et al.* Use and impact of high intensity treatments in patients with traumatic brain injury across Europe: a CENTER-TBI analysis. *Crit Care* 2021; **25**: 78.

- 13 Bhattacharyay S, Caruso PF, Åkerlund C, *et al.* Mining the contribution of intensive care clinical course to outcome after traumatic brain injury. *Npj Digit Med* 2023; **6**: 1– 11.
- 14 Huijben JA, Wiegers EJA, Lingsma HF, *et al.* Changing care pathways and between-center practice variations in intensive care for traumatic brain injury across Europe: a CENTER-TBI analysis. *Intensive Care Med* 2020; **46**: 995–1004.
- 15 Bhattacharyay S, Milosevic I, Wilson L, *et al.* The leap to ordinal: Detailed functional prognosis after traumatic brain injury with a flexible modelling approach. *PLOS ONE* 2022; **17**: e0270973.
- 16 Doiron D, Marcon Y, Fortier I, Burton P, Ferretti V. Software Application Profile: Opal and Mica: open-source software solutions for epidemiological data management, harmonization and dissemination. *Int J Epidemiol* 2017; **46**: 1372–8.
- 17 Monteiro M, Newcombe VFJ, Mathieu F, *et al.* Multiclass semantic segmentation and quantification of traumatic brain injury lesions on head CT using deep learning: an algorithm development and multicentre validation study. *Lancet Digit Health* 2020; **2**: e314–22.
- 18 Jain S, Vyvere TV, Terzopoulos V, *et al.* Automatic Quantification of Computed Tomography Features in Acute Traumatic Brain Injury. *J Neurotrauma* 2019; **36**: 1794–803.
- 19 Deasy J, Liò P, Ercole A. Dynamic survival prediction in intensive care units from heterogeneous time series without the need for variable selection or curation. *Sci Rep* 2020; **10**: 22129.
- 20 Ercole A, Dixit A, Nelson DW, *et al.* Imputation strategies for missing baseline neurological assessment covariates after traumatic brain injury: A CENTER-TBI study. *PLOS ONE* 2021; **16**: e0253425.
- 21 Tsamardinos I, Greasidou E, Borboudakis G. Bootstrapping the out-of-sample predictions for efficient and accurate cross-validation. *Mach Learn* 2018; **107**: 1895– 922.
- 22 Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. *J Clin Epidemiol* 2016; **74**: 167–76.
- 23 Somers RH. A New Asymmetric Measure of Association for Ordinal Variables. *Am Sociol Rev* 1962; **27**: 799–811.
- 24 Van Calster B, Van Belle V, Vergouwe Y, Steyerberg EW. Discrimination ability of prediction models for ordinal outcomes: Relationships between existing measures and a new measure. *Biom J* 2012; **54**: 674–85.

 25 Bento J, Saleiro P, Cruz AF, Figueiredo MAT, Bizarro P. TimeSHAP: Explaining Recurrent Models through Sequence Perturbations. In: Proceedings of the 27th ACM SIGKDD Conference on Knowledge Discovery & Data Mining. New York, NY, USA:

- Association for Computing Machinery, 2021: 2565–73.
- 26 Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. In:
- Guyon I, Luxburg UV, Bengio S, *et al.*, eds. Advances in Neural Information Processing Systems 30. NIPS, 2017: 4765–74.
- 27 Shapley LS. A Value for n-Person Games. In: Contributions to the Theory of Games II. Princeton University Press, 1953: 307–18.
- 28 Brossard C, Grèze J, de Busschère J-A, *et al.* Prediction of therapeutic intensity level from automatic multiclass segmentation of traumatic brain injury lesions on CT-scans. *Sci Rep* 2023; **13**: 20155.
- 29 Åkerlund CAI, Holst A, Stocchetti N, *et al.* Clustering identifies endotypes of traumatic brain injury in an intensive care cohort: a CENTER-TBI study. *Crit Care* 2022; **26**: 228.
- 30 Åkerlund CAI, Holst A, Bhattacharyay S, *et al.* Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study. *Lancet Neurol* 2024; **23**: 71–80.
- 31 Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. *J Neurol Neurosurg Psychiatry* 2004; **75**: 813–21.
- 32 Åkerlund CAI, Donnelly J, Zeiler FA, *et al.* Impact of duration and magnitude of raised intracranial pressure on outcome after severe traumatic brain injury: A CENTER-TBI high-resolution group study. *PLOS ONE* 2020; **15**: e0243427.
- 33 Beqiri E, Ercole A, Aries MJH, *et al.* Towards autoregulation-oriented management after traumatic brain injury: increasing the reliability and stability of the CPPopt algorithm. *J Clin Monit Comput* 2023; **37**: 963–76.
- 34 Zoerle T, Birg T, Carbonara M, *et al.* Accuracy of Manual Intracranial Pressure Recording Compared to a Computerized High-Resolution System: A CENTER-TBI Analysis. *Neurocrit Care* 2023; **38**: 781–90.
- 35 Eiden M, Christinat N, Chakrabarti A, *et al.* Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients. *eBioMedicine* 2019; **44**: 607–17.
- 36 Banco P, Taccone FS, Sourd D, *et al.* Prediction of neurocritical care intensity through automated infrared pupillometry and transcranial doppler in blunt traumatic brain injury: the NOPE study. *Eur J Trauma Emerg Surg* 2024; published online Jan 16. DOI:10.1007/s00068-023-02435-1.

- 37 Luz Teixeira T, Peluso L, Banco P, *et al.* Early Pupillometry Assessment in Traumatic Brain Injury Patients: A Retrospective Study. *Brain Sci* 2021; **11**: 1657.
- 38 Bhattacharyay S, Rattray J, Wang M, *et al.* Decoding accelerometry for classification and prediction of critically ill patients with severe brain injury. *Sci Rep* 2021; **11**: 23654.
- 39 Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World Patient Data to Individualized Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges. *Clin Pharmacol Ther* 2020; **109**: 87–100.
- 40 Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. *Npj Digit Med* 2020; **3**: 1–10.
- 41 Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability in clinical research and machine learning in health care. *Lancet Digit Health* 2020; **2**: e489–92.
- 42 Clark D, Joannides A, Adeleye AO, *et al.* Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study. *Lancet Neurol* 2022; **21**: 438–49.